A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Nilotinib (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2019.
- 28 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Jan 2018.